Current Portfolio
EQT invests in good companies with a mission to help them develop into great companies.
Half-year Report 2025
EQT invests in good companies with a mission to help them develop into great companies.
Company | Sector | Fund | Market | Entry |
|---|---|---|---|---|
| Agomab Therapeutics | Life Sciences | LSP 7 | Belgium | 2023 |
| Am-Pharma | Life Sciences | LSP 6 | Netherlands | 2019 |
| Ariceum Therapeutics | Life Sciences | LSP 7 | Germany | 2021 |
| Artios Pharma | Life Sciences | LSP 6 | United Kingdom | 2018 |
| Atalanta Therapeutics | Life Sciences | LSP Dementia Fund | United States | 2024 |
| Atlantic Therapeutics | Life Sciences | LSP HEF 2 | Ireland | 2018 |
| Avidicure | Life Sciences | LSP 7 | Netherlands | 2024 |
| Binx Health | Life Sciences | LSP 4 | United Kingdom | 2011 |
| Binx Health | Life Sciences | LSP 6 | United Kingdom | 2016 |
| Cardiac Dimensions | Life Sciences | LSP HEF 1 | United States | 2015 |
| DNA Script | Life Sciences | LSP 6 | France | 2019 |
| DOTS Technology | Life Sciences | LSP HEF 2 | United States | 2021 |
| Egle Therapeutics | Life Sciences | LSP 7 | France | 2021 |
| Eloxx Pharma | Life Sciences | LSP 5 | United States | 2017 |
| eTheRNA | Life Sciences | LSP 5 | Belgium | 2016 |
| Evommune | Life Sciences | LSP 7 | United States | 2021 |
| Eyesense | Life Sciences | LSP 3 | Switzerland | 2006 |
| FoRx Therapeutics | Life Sciences | LSP 6 | Switzerland | 2019 |
| Fundamental VR | Life Sciences | LSP HEF 2 | United Kingdom | 2022 |
| HotSpot Therapeutics | Life Sciences | LSP 7 | United States | - |
| Illuminoss | Life Sciences | LSP HEF 1 | United States | 2012 |
| ImCheck | Life Sciences | LSP 5 | France | 2017 |
| Imcyse | Life Sciences | LSP 6 | Belgium | 2019 |
| Immunic | Life Sciences | LSP 5 | Germany | 2016 |
| Innovative Molecules | Life Sciences | LSP 6 | Germany | 2021 |
| iStar Medical | Life Sciences | LSP HEF 2 | Belgium | 2019 |
| Luma Vision | Life Sciences | LSP HEF 2 | Ireland & Germany | 2020 |
| Medeye | Life Sciences | LSP HEF 1 | Netherlands | 2014 |
| Merus | Life Sciences | LSP 4 | Netherlands | 2010 |
| MinervaX | Life Sciences | LSP 7 | Denmark | 2023 |
| Muna Therapeutics | Life Sciences | LSP Dementia Fund | Denmark | 2021 |
| Neurent Medical | Life Sciences | LSP HEF 2 | Ireland | 2020 |
| New Amsterdam Pharma | Life Sciences | LSP Dementia Fund | Netherlands | 2021 |
| Nkarta | Life Sciences | LSP 6 | United States | 2019 |
| Nobi | Life Sciences | LSP HEF 2 | Belgium | 2022 |
| Nobi | Life Sciences | LSP Dementia Fund | Belgium | 2022 |
| Noema Pharma | Life Sciences | LSP 7 | Switzerland | 2024 |
| Nouscom | Life Sciences | LSP 5 | Switzerland | 2015 |
| Nua Surgical | Life Sciences | Ireland | 2024 | |
| Oculis | Life Sciences | LSP 7 | Switzerland | 2022 |
| Onera Health | Life Sciences | Netherlands | 2024 | |
| ONWARD | Life Sciences | LSP 5 | Netherlands | 2016 |
| Orphazyme | Life Sciences | LSP 5 | Denmark | 2017 |
| OxThera | Life Sciences | LSP 5 | Sweden | 2016 |
| Pantera | Life Sciences | LSP 7 | Belgium | 2024 |
| Perfuze | Life Sciences | LSP HEF 2 | Ireland | 2022 |
| Phagenesis | Life Sciences | United Kingdom | 2024 | |
| Pharvaris | Life Sciences | LSP 5 | Germany | 2016 |
| Sequana Medical | Life Sciences | LSP HEF 1 | Belgium | 2014 |
| Shinobi Therapeutics | Life Sciences | LSP 7 | United States | 2023 |
| SNIPR Biome | Life Sciences | LSP 6 | Denmark | 2019 |
| T-Knife | Life Sciences | LSP 6 | Germany | 2021 |
| Tenpoints Therapeutics | Life Sciences | LSP 6 | United States | 2021 |
| Tubulis | Life Sciences | LSP 7 | Germany | 2024 |
| VarmX | Life Sciences | LSP 6 | Netherlands | 2020 |
| VectorY | Life Sciences | LSP Dementia Fund | Netherlands | 2023 |
| ViCentra | Life Sciences | LSP HEF 2 | Netherlands | 2021 |
| ViCentra | Life Sciences | LSP 5 | Netherlands | 2016 |
| ViCentra | Life Sciences | LSP HEF 1 | Netherlands | 2016 |
| Vico Therapeutics | Life Sciences | LSP 6 | Belgium | 2019 |
| Vivasure | Life Sciences | LSP HEF 1 | Ireland | 2016 |
| Xeltis | Life Sciences | LSP HEF 1 | Netherlands | 2014 |
| Xeltis | Life Sciences | LSP HEF 2 | Netherlands | 2022 |
| Xilis | Life Sciences | LSP 6 | United States | 2021 |
| XyloCor Therapeutics | Life Sciences | LSP 6 | United States | 2018 |